SI3453723T1 - Protitelesa proti-ASIC1 in njihove uporabe - Google Patents

Protitelesa proti-ASIC1 in njihove uporabe

Info

Publication number
SI3453723T1
SI3453723T1 SI201331923T SI201331923T SI3453723T1 SI 3453723 T1 SI3453723 T1 SI 3453723T1 SI 201331923 T SI201331923 T SI 201331923T SI 201331923 T SI201331923 T SI 201331923T SI 3453723 T1 SI3453723 T1 SI 3453723T1
Authority
SI
Slovenia
Prior art keywords
asic1 antibodies
asic1
antibodies
Prior art date
Application number
SI201331923T
Other languages
English (en)
Slovenian (sl)
Inventor
Lynn Macdonald
Min Gao
Marc R Morra
Nicole M Alessandri-Haber
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3453723(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of SI3453723T1 publication Critical patent/SI3453723T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201331923T 2012-01-31 2013-01-30 Protitelesa proti-ASIC1 in njihove uporabe SI3453723T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24
EP18201823.4A EP3453723B1 (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SI3453723T1 true SI3453723T1 (sl) 2021-11-30

Family

ID=47666522

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331923T SI3453723T1 (sl) 2012-01-31 2013-01-30 Protitelesa proti-ASIC1 in njihove uporabe
SI201331343T SI2809681T1 (sl) 2012-01-31 2013-01-30 Protitelesa anti-asic1 in njihova uporaba

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201331343T SI2809681T1 (sl) 2012-01-31 2013-01-30 Protitelesa anti-asic1 in njihova uporaba

Country Status (33)

Country Link
US (3) US9150648B2 (OSRAM)
EP (2) EP3453723B1 (OSRAM)
JP (1) JP6302844B2 (OSRAM)
KR (1) KR102111941B1 (OSRAM)
CN (1) CN104093738B (OSRAM)
AR (1) AR089852A1 (OSRAM)
AU (1) AU2013215254B2 (OSRAM)
CA (1) CA2862332C (OSRAM)
CL (1) CL2014002019A1 (OSRAM)
CO (1) CO7020877A2 (OSRAM)
CY (2) CY1121368T1 (OSRAM)
DK (2) DK2809681T3 (OSRAM)
EA (1) EA028647B1 (OSRAM)
ES (2) ES2707599T3 (OSRAM)
HR (2) HRP20190358T1 (OSRAM)
HU (2) HUE056335T2 (OSRAM)
IL (2) IL233410A0 (OSRAM)
IN (1) IN2014CN04645A (OSRAM)
JO (1) JO3547B1 (OSRAM)
LT (2) LT2809681T (OSRAM)
MX (1) MX358518B (OSRAM)
MY (1) MY168748A (OSRAM)
NZ (1) NZ626242A (OSRAM)
PH (1) PH12014501613A1 (OSRAM)
PL (2) PL2809681T3 (OSRAM)
PT (2) PT2809681T (OSRAM)
RS (2) RS62454B1 (OSRAM)
SG (1) SG11201403222UA (OSRAM)
SI (2) SI3453723T1 (OSRAM)
SM (1) SMT202100628T1 (OSRAM)
TW (1) TWI591073B (OSRAM)
UY (1) UY34603A (OSRAM)
WO (1) WO2013116296A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056335T2 (hu) 2012-01-31 2022-02-28 Regeneron Pharma ASIC1-ellenes antitestek és alkalmazásaik
US10272154B2 (en) 2014-04-15 2019-04-30 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
SI3248986T1 (sl) 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
CN111936517B (zh) * 2018-01-26 2025-04-18 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段
JP7496626B2 (ja) * 2019-06-04 2024-06-07 シャンハイテック ユニバーシティ 親和性成熟抗ＡＳＩＣ１ａ抗体
CN119080930A (zh) 2019-07-11 2024-12-06 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
CN114867745B (zh) * 2019-07-23 2024-01-12 上海科技大学 Asic1通道拮抗剂抗体
EP4028422A4 (en) * 2019-09-13 2024-01-10 Memorial Sloan-Kettering Cancer Center ANTI-CD371 ANTIBODIES AND THEIR USES
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
WO2023034566A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-dll3 antibodies and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
CA2308014A1 (en) 1997-10-29 1999-05-06 Mcgill University Dna encoding a human proton-gated ion channel and uses thereof
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
DK1527100T3 (da) * 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
WO2005025518A2 (en) * 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
CA2561993A1 (en) 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
JP4884395B2 (ja) * 2004-12-21 2012-02-29 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
KR101203328B1 (ko) * 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008007648A1 (fr) * 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
EP2043650A2 (en) 2006-07-14 2009-04-08 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DE602008002913D1 (de) 2007-04-03 2010-11-18 Ilegusavnid Genetics Resource Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
EP2392597B1 (en) * 2007-04-27 2014-04-02 ZymoGenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2853897A1 (en) * 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
HUE056335T2 (hu) 2012-01-31 2022-02-28 Regeneron Pharma ASIC1-ellenes antitestek és alkalmazásaik

Also Published As

Publication number Publication date
AU2013215254A1 (en) 2014-07-03
HK1199269A1 (en) 2015-06-26
PH12014501613B1 (en) 2014-10-13
PL2809681T3 (pl) 2019-05-31
MX2014008541A (es) 2014-10-24
CL2014002019A1 (es) 2015-01-16
JP6302844B2 (ja) 2018-03-28
SI2809681T1 (sl) 2019-04-30
PT2809681T (pt) 2019-02-18
PH12014501613A1 (en) 2014-10-13
IL233410A0 (en) 2014-08-31
JO3547B1 (ar) 2020-07-05
DK3453723T3 (da) 2021-09-13
CY1121368T1 (el) 2020-05-29
WO2013116296A1 (en) 2013-08-08
KR102111941B1 (ko) 2020-05-18
CY1124778T1 (el) 2022-11-25
UY34603A (es) 2013-07-31
US10513557B2 (en) 2019-12-24
MY168748A (en) 2018-11-30
ES2707599T3 (es) 2019-04-04
EA201491452A1 (ru) 2014-11-28
LT2809681T (lt) 2019-02-11
EP3453723A2 (en) 2019-03-13
US20130195878A1 (en) 2013-08-01
EP2809681B1 (en) 2018-12-05
US20160002332A1 (en) 2016-01-07
EP3453723A3 (en) 2019-04-10
ES2886123T3 (es) 2021-12-16
HUE042531T2 (hu) 2019-07-29
PL3453723T3 (pl) 2022-01-03
CN104093738B (zh) 2018-05-18
IN2014CN04645A (OSRAM) 2015-09-18
CN104093738A (zh) 2014-10-08
HRP20190358T1 (hr) 2019-04-05
LT3453723T (lt) 2021-09-10
BR112014018651A2 (pt) 2017-07-04
SMT202100628T1 (it) 2022-01-10
PT3453723T (pt) 2021-09-07
IL254416A0 (en) 2017-11-30
EP2809681A1 (en) 2014-12-10
HRP20211541T1 (hr) 2021-12-24
KR20140125363A (ko) 2014-10-28
US9150648B2 (en) 2015-10-06
RS58439B1 (sr) 2019-04-30
SG11201403222UA (en) 2014-07-30
CA2862332C (en) 2021-05-18
AU2013215254B2 (en) 2017-08-31
RS62454B1 (sr) 2021-11-30
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
EP3453723B1 (en) 2021-08-11
IL254416B (en) 2018-03-29
NZ626242A (en) 2017-02-24
JP2015508063A (ja) 2015-03-16
CA2862332A1 (en) 2013-08-08
US20180222976A1 (en) 2018-08-09
DK2809681T3 (en) 2019-03-11
TW201335182A (zh) 2013-09-01
AR089852A1 (es) 2014-09-24
TWI591073B (zh) 2017-07-11
MX358518B (es) 2018-08-24
HUE056335T2 (hu) 2022-02-28

Similar Documents

Publication Publication Date Title
IL288203A (en) Meditops and Meditop binding antibodies and their use
IL259436A (en) Antibodies against 3angptl and their uses
IL238559B (en) Antibodies against ceacam5 and their use
IL232399A0 (en) Anti-2fgfr antibodies and their use
IL254416B (en) Anti-asic1 antibodies and their uses
EP2832856A4 (en) ANTI-LAMP5 ANTIBODIES AND USE THEREOF
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
GB201208372D0 (en) Antibodies and uses thereof